Human LRIG3 ELISA Kit

Name: Human LRIG3 ELISA Kit
SKU: DEIABL655
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cell culture supernates, serum, heparin plasma

Species Reactivity

Human

Intended Use

Sandwich High Sensitivity ELISA kit for Quantitative Detection of Human LRIG3.

Storage

Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles(Shipped with wet ice.)

Detection Range

62.5pg/ml-4000pg/ml

Sensitivity

<12pg/ml

Citations

Have you cited DEIABL655 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor

JOURNAL OF THE NEUROLOGICAL SCIENCES

Authors: Guo, Dongsheng; Yang, Hongkuan; Guo, Yang; Xiao, Qungen; Mao, Feng; Tan, Yihu; Wan, Xueyan; Wang, Baofeng; Lei, Ting

Abstract

Leucine-rich repeats and immunoglobulin-like domains (LRIG) 3 gene is mapped to chromosome 12q13.2, a region that is frequently deleted in a subset of glioblastoma multiforme (GBM). It has been reported that perinuclear LRIG3 staining correlated with low WHO grade of glioma and better survival of the patients. However, the relationship between LRIG3 and glioma is not very clear. The purpose of this study is to demonstrate the impacts of LRIG3 on biological characteristics of glioma and its possible mechanisms. We found that transduction of LRIG3 into glioblastoma cells inhibited cell growth in vitro and in vivo, promoted cell apoptosis, and restrained cell invasion and migration. Further studies demonstrated that LRIG3 negatively regulated the epidermal growth factor receptor (EGFR) signaling pathway. Inhibition of EGFR could reduce the effects of LRIG3 knockdown on cell proliferation and EGFR signaling pathway. In conclusion, LRIG3 functions as a tumor suppressor by attenuating EGFR signaling pathway and the restoration of LRIG3 may offer therapeutic potential against malignant gliomas. (C) 2015 Elsevier B.V. All rights reserved.

Leucine-rich Repeat and Immunoglobulin Domain-containing Protein-1 (Lrigl) Negative Regulatory Action toward ErbB Receptor Tyrosine Kinases Is Opposed by Leucine-rich Repeat and Immunoglobulin Domain-containing Protein 3 (Lrig3)

JOURNAL OF BIOLOGICAL CHEMISTRY

Authors: Rafidi, Hanine; Mercado, Francisco, III; Astudillo, Michael; Fry, William H. D.; Saldana, Matthew; Carraway, Kermit L., III; Sweeney, Colleen

Abstract

Lrig1 is the founding member of the Lrig family of transmembrane leucine-rich repeat proteins, which also includes Lrig2 and Lrig3. Lrig1 is a negative regulator of oncogenic receptor tyrosine kinases, including ErbB and Met receptors, and promotes receptor degradation. Lrig1 has recently emerged as both a tumor suppressor and a key regulator of epidermal and epithelial stem cell quiescence. Despite this, little is known of the mechanisms by which Lrig1 is regulated. Lrig3 was recently reported to increase ErbB receptor expression suggesting that it may function in a manner opposite to Lrig1. In this study, we explore the interaction between Lrig1 and Lrig3 and demonstrate that Lrig1 and Lrig3 functionally oppose one another. Lrig3 opposes Lrig1 negative regulatory activity and stabilizes ErbB receptors. Conversely, Lrig1 destabilizes Lrig3, limiting Lrig3's positive effects on receptors and identifying Lrig3 as a new target of Lrig1. These studies provide new insight into the regulation of Lrig1 and uncover a complex cross-talk between Lrig1 and Lrig3.